- Open
- 0.07
- High
- 0.07
- Low
- 0.05
- Close
- 0.07
- Change
- -0.01 (-7.69%)
- Volume
- 99,787,984
| 11 Nov 2026 | 07:00:05 | Proposed Acquisition of Biovara |
| 19 Oct 2026 | 07:00:07 | NXP002 Development Update |
| 25 Aug 2026 | 07:00:03 | Appointment of Chairman |
| 19 Aug 2026 | 07:00:03 | NXP002 Development Update |
| 23 Feb 2026 | Annual Report and Accounts (to 2025-09-30) | |
| 3 Feb 2025 | Annual Report and Accounts (to 2024-09-30) | |
| 19 Mar 2024 | Annual Report and Accounts (to 2023-09-30) |
Nuformix plc is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing. The company specializes in discovering and developing novel drug forms with improved physical properties, particularly its lead program NXP002, which is an inhaled treatment for progressive fibrosing interstitial lung diseases, including Idiopathic Pulmonary Fibrosis. Nuformix operates primarily in the preclinical stage, targeting markets in the United States and Europe, and aims to secure licensing or collaborative agreements to advance its product pipeline.
| 11 Nov 2026 | 07:00:05 | Proposed Acquisition of Biovara |
| 19 Oct 2026 | 07:00:07 | NXP002 Development Update |
| 25 Aug 2026 | 07:00:03 | Appointment of Chairman |
| 19 Aug 2026 | 07:00:03 | NXP002 Development Update |
| 23 Feb 2026 | Annual Report and Accounts (to 2025-09-30) | |
| 3 Feb 2025 | Annual Report and Accounts (to 2024-09-30) | |
| 19 Mar 2024 | Annual Report and Accounts (to 2023-09-30) |
Nuformix plc is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing. The company specializes in discovering and developing novel drug forms with improved physical properties, particularly its lead program NXP002, which is an inhaled treatment for progressive fibrosing interstitial lung diseases, including Idiopathic Pulmonary Fibrosis. Nuformix operates primarily in the preclinical stage, targeting markets in the United States and Europe, and aims to secure licensing or collaborative agreements to advance its product pipeline.
| 28 May 2026 |
| 07:00:03 |
| Half Year Report |
| 11 Nov 2026 |
| Nuformix to acquire Biovara in deal to combine two respiratory drug programmes |
| 19 Oct 2026 | Nuformix reports further positive NXP002 results demonstrating TGF-β pathway modulation |
| 25 Aug 2026 | Nuformix appoints Tim Metcalfe as Non-Executive Chairman |
| 21 Aug 2026 | Nuformix adds new preclinical support for NXP002 |
| 21 Aug 2026 | Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video) |
| 19 Aug 2026 | Nuformix gains 19% in London trade on positive NXP002 study ahead of ERS Congress |
| 28 May 2026 |
| 07:00:03 |
| Half Year Report |
| 11 Nov 2026 |
| Nuformix to acquire Biovara in deal to combine two respiratory drug programmes |
| 19 Oct 2026 | Nuformix reports further positive NXP002 results demonstrating TGF-β pathway modulation |
| 25 Aug 2026 | Nuformix appoints Tim Metcalfe as Non-Executive Chairman |
| 21 Aug 2026 | Nuformix adds new preclinical support for NXP002 |
| 21 Aug 2026 | Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video) |
| 19 Aug 2026 | Nuformix gains 19% in London trade on positive NXP002 study ahead of ERS Congress |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £98m | -0.2% | |
| £16m | -0.7% | |
| £6m | -0.7% | |
| £3m | -0.8% | |
| £2m | -0.0% | |
NFXNuformix plc | £2m | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £98m | -0.2% | |
| £16m | -0.7% | |
| £6m | -0.7% | |
| £3m | -0.8% | |
| £2m | -0.0% | |
NFXNuformix plc | £2m | -0.8% |